Updated:
Beijing Novogene Bioinformatics Technology
Beijing Novogene Bioinformatics Technology was established in 2011 by Dr. Li Ruiqiang. The founder serves as chairman and chief executive. The firm delivers...
Beijing Novogene Bioinformatics Technology
Beijing Novogene Bioinformatics Technology was established in 2011 by Dr. Li Ruiqiang. The founder serves as chairman and chief executive. The firm delivers genomic technology services, tumor detection and genetic testing. Asset deployment occurs through direct operations and co-investments with SDIC Innovation, CMB International Capital and Sigma Square Capital. Geographic reach covers China, Hong Kong, the United States and the United Kingdom. Additional facilities include a Tianjin medical laboratory, Cambridge Sequencing Center and Sacramento Sequencing Center. No recent operational events from the last 24 months appear in available records. The corporate structure ties investment activity directly to the operating company's sequencing platform and high-performance computing assets.
General information
Firm type
Corporate Investor
Year founded
2011
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Beijing
Corporate office
Beijing, China
Additional offices
Hong Kong · United States · United Kingdom
Principals
Dr. Li Ruiqiang
Founder, Chairman, and CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Beijing Novogene Bioinformatics Technology?
Dr. Li Ruiqiang serves as founder, chairman and CEO. Investment activity aligns with the firm's core sequencing and testing operations.
Does Beijing Novogene Bioinformatics Technology participate in fund commitments or only direct deals?
Activity centers on direct operational investments and select institutional partnerships. SDIC Innovation and CMB International Capital participated in funding rounds.
Where does Beijing Novogene Bioinformatics Technology maintain sequencing facilities?
Facilities operate in Beijing, Tianjin, Cambridge in the United Kingdom and Sacramento in the United States.
Which institutional investors have backed Beijing Novogene Bioinformatics Technology?
SDIC Innovation, CMB International Capital and Sigma Square Capital have participated in funding rounds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: